PanSYM-1 is an ongoing prospective validation study for the early diagnosis of pancreatic cancer in patients with vague but concerning symptoms and other risk factors.
Testing for pancreatic cancer in patients with vague, non-specific but concerning symptoms
The early symptoms of pancreatic cancer are often vague, making the disease difficult to detect. On average, it takes 6-9 months and 18 visits to the doctor before a patient with pancreatic cancer is actually diagnosed with cancer.
Testing for pancreatic cancer in risk groups with early, vague but concerning symptoms with IMMray™ PanCan-d could help clinicians to diagnose the cancer while it is still resectable by surgery, thereby dramatically improving survival rates, and at the same time lowering healthcare costs.
To this purpose, Immunovia is working actively on a global basis with Key Opinion Leaders (KOL) in an attempt to influence medical practice and national guidelines. The goal is to achieve routine testing of patients with vague but concerning symptom profiles were the clinician suspects – or wants to rule out – pancreatic cancer. In July 2017, one of the worlds most renowned experts in pancreatic cancer, Professor Stephen Pereira at the University College London Hospital joined the advisory board.
In 2018, in close collaboration with UCLH, and Prof Pereira, Immunovia started PanSYM-1, a prospective collection of serum samples from high risk patients with vague but concerning symptoms attending secondary care centers and endoscopy / gastrointestinal units. These samples are now part of the development stages of IMMray™ PanCan-d: the optimization study, the commercial test model study, verification and validation study.
As soon as IMMray™ PanCan-d is validated, a prospective interventional phase of PanSYM-1 will commence at UCLH and several other rapid diagnostic centers across UK analysing over 2000 patients with non-specific but concerning symptoms profiles to assess utility of Immunovias test in identifying the high risk patients earlier than the current standard. PanSYM-1 prospective study is part of UCL ADEPTS Study (Accelerated Diagnosis of neuro Endocrine and Pancreatic TumourS) funded by Pancreatic Cancer UK to support significant elements of the NHS (national healthcare system in England) long term plan set 2019 with one main goal being cancer diagnosis at resectable stage. (Press release April 10, 2019)
- Suresh T. Chari et al. Summative Review: “Early Detection of Sporadic Pancreatic Cancer”, 2015
- Fiona M Walter et al. Symptoms and patient factors associated with diagnostic intervals for pancreatic cancer (SYMPTOM pancreatic study): a prospective cohort study, Lancet Gastroenterol Hepatol 2016.
- ACE Cancer Decision Support Tools Cluster “Using Cancer Decision Support Tools to support the early diagnosis of cancer”, May 2017
- Keane MG et al. A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 2014;4:e005720. doi:10.1136/bmjopen-2014-005720